Sunesis Pharmaceuticals, Inc.
(NASDAQ : SNSS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.90%194.181.2%$592.16m
GILDGilead Sciences, Inc.
-0.83%69.200.9%$496.51m
BIIBBiogen Inc.
0.72%324.051.3%$476.94m
CELGCelgene Corporation
-0.47%69.651.2%$474.00m
ILMNIllumina, Inc.
0.13%319.933.5%$402.89m
REGNRegeneron Pharmaceuticals, Inc.
1.08%345.332.6%$297.08m
VRTXVertex Pharmaceuticals Incorporated
-0.94%165.111.9%$277.86m
ALXNAlexion Pharmaceuticals, Inc.
-0.89%118.622.0%$201.35m
AAgilent Technologies, Inc.
0.42%64.991.5%$188.27m
EXASExact Sciences Corporation
3.65%71.3825.3%$147.45m
SRPTSarepta Therapeutics, Inc.
0.07%119.0415.4%$145.09m
LGNDLigand Pharmaceuticals Incorporated
1.68%154.4623.3%$145.09m
ECYTEndocyte, Inc.
0.25%23.672.0%$124.13m
INCYIncyte Corporation
2.28%66.512.5%$117.76m
NKTRNektar Therapeutics
0.11%38.235.6%$117.70m

Company Profile

Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Its efforts are currently focused primarily on the development of vosaroxin for the treatment of acute myeloid leukemia. The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.